Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual MeetingAbstract 4525: Hematologic responses and cardiac organ improvement in patients with heavily pretreated cardiac AL amyloidosis receiving daratumumab
0:53 minutes.
TRANSCRIPTION:
DR MIKHAEL: The other abstract that was significant in amyloidosis was introducing daratumumab. We all know that daratumumab is a monoclonal antibody directed against CD38 that has really had a profound impact in relapsed myeloma and will likely be used in up-front myeloma. And there was a small study presented looking back in Stanford at their experience in using daratumumab in patients with amyloidosis who had been pretreated. And, no surprise, we see benefit from it. Again, anything that is going to reduce those plasma cells from making light chains that can ultimately be deposited as amyloid will be of benefit. So I’m not sure that daratumumab is quite ready for prime time yet in amyloidosis, but I think in the very near future we’re going to add it to our armamentarium of drugs to try and prevent the amyloid deposition that we see. |